| __timestamp | ImmunityBio, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1595000 | 19586000 |
| Thursday, January 1, 2015 | 11434000 | 29135000 |
| Friday, January 1, 2016 | 26546000 | 42791000 |
| Sunday, January 1, 2017 | 39778000 | 49577000 |
| Monday, January 1, 2018 | 53418000 | 89209000 |
| Tuesday, January 1, 2019 | 111997000 | 69099000 |
| Wednesday, January 1, 2020 | 139507000 | 75961000 |
| Friday, January 1, 2021 | 195958000 | 90467000 |
| Saturday, January 1, 2022 | 248149000 | 74552000 |
| Sunday, January 1, 2023 | 232366000 | 91593000 |
Unleashing the power of data
In the ever-evolving world of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, ImmunityBio, Inc. and Supernus Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments.
ImmunityBio, Inc. has shown a remarkable increase in R&D spending, growing from a modest $1.6 million in 2014 to a staggering $232 million by 2023. This represents an impressive growth rate of over 14,000%, underscoring their aggressive pursuit of groundbreaking therapies.
In contrast, Supernus Pharmaceuticals, Inc. has maintained a more consistent R&D investment strategy. Starting at $19.6 million in 2014, their spending reached $91.6 million in 2023, marking a steady growth of approximately 367%. This approach reflects a balanced strategy, focusing on sustainable innovation.
These trends highlight the diverse approaches within the pharmaceutical industry, where both aggressive and steady investment strategies can lead to success.
Research and Development: Comparing Key Metrics for Novo Nordisk A/S and Supernus Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and Supernus Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Biogen Inc. and Supernus Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for United Therapeutics Corporation and ImmunityBio, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and Supernus Pharmaceuticals, Inc.
Analyzing R&D Budgets: Sarepta Therapeutics, Inc. vs ImmunityBio, Inc.
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.
R&D Insights: How Corcept Therapeutics Incorporated and ImmunityBio, Inc. Allocate Funds
R&D Insights: How Corcept Therapeutics Incorporated and Supernus Pharmaceuticals, Inc. Allocate Funds
Analyzing R&D Budgets: Apellis Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Breaking Down Revenue Trends: ImmunityBio, Inc. vs Supernus Pharmaceuticals, Inc.
Analyzing R&D Budgets: Supernus Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.